Cannabis Industry Insights

A 240-Patient Study Makes the Case That Cannabis Can Spare Opioids

The most clinically meaningful cannabis study of the week did not involve a flashy molecule or a dramatic cure. It involved 240 patients living with a poorly understood, chronically painful condition

The 10-Milligram Rush — Cannabis Drinks Bulk Up Before the Federal Clock Runs Out

There is a quiet arms race underway in the cannabis beverage aisle, and this week it got louder.

As Rescheduling Inches Forward, Its Opponents Open a New Front in Court

Trulieve Rings the NYSE Bell — and the Industry Discovers Wall Street Was Never the Hard Part

For more than a decade, the dream of every American cannabis executive sounded roughly the same: someday, a plant-touching operator would trade on a major U.S. stock exchange like any other consumer business.

800 Milligrams of CBD and a Hard Truth About What Cannabis Can and Can't Treat

For the millions of people living with the relentless nerve pain that follows a spinal cord injury, the options have always been grim

The Sober-Curious Cannabis Drink Has Its Data — and a Big Week of Launches to Match

The most important cannabis product of the week wasn't a flashy new strain or a celebrity edible. It was a spreadsheet. On June 4, MoreBetter and the Network of Applied Pharmacognosy released findings from the largest real-world cannabis beverage study to date.

The Clock Is Ticking on Two Fronts: A June Hearing for Marijuana, a July Deadline for Hemp

Cannabis policy in America has rarely felt as bifurcated as it does this week. On one track, marijuana is moving — haltingly, contentiously — toward looser federal control. On another, the hemp-derived products that have flooded gas stations and smoke shops are being squeezed toward extinction.

Cannabis Stocks Land on Robinhood as Alabama Cuts the Ribbon

For years, the American cannabis industry has operated like a business hiding in plain sight: legal in most states, banned by the federal government, and walled off from the ordinary machinery of capital and commerce. This week, two of those walls quietly came down at once.

A Brownie, a Drink, and a Driving Test That Doesn't Work: The Week's Most Important Cannabis Science

Science can sometimes feel like it moves slower than the culture around it. For cannabis, that gap has been a defining feature of the last decade — millions of Americans using a substance while the research needed to understand its risks and benefits lags years, sometimes decades, behind the conversation.

Vapes, Pre-Rolls, and the Price of Progress: What This Week's Product Moves Say About Where Cannabis Is Headed

Cannabis product news this week told a story that has become increasingly familiar in 2026: the industry is maturing fast, but it's doing so unevenly, with some categories racing ahead while others fight for shelf space in an increasingly crowded market.